Advertisement
Advertisement

More Related Content

Advertisement
Advertisement

Serotonin pharmacology

  1. By :- Ali Al-Alwani Group:-117 i-6
  2. Introduction Synthesis. Degradation. Serotonin Receptors. Pathways in Brain. Disorders associated with malfunctioned Serotonergic System. Drugs affecting on serotonergic System
  3. Types of neurotransmitters: Although over 50 signal molecules in the nervous system have been identified, norepinephrine (and the closely related epinephrine), acetylcholine, dopamine, serotonin, histamine, glutamate, and γ-aminobutyric acid are most commonly involved in the actions of therapeutically useful drugs.
  4. Serotonin is a monoamine neurotransmitter. It has a popular image as a contributor to feelings of well-being and happiness extensively in GIT 80 to 90 percent - enterochromaffin cells in the gut, where it is used to regulate intestinal movements. The remainder is synthesizedin serotonergic neurons in the central nervous system. Despite the abundance of peripheral serotonin, its inability to cross the BBB necessitates the synthesis of serotonin within the brain. Serotonin is synthesized from the amino acid tryptophan, which is derived from the diet. Introduction
  5. Serotonin secreted from the enterochromaffin cells eventually finds its way out of tissues into the blood. There, it is actively taken up by blood platelets, which store it. When the platelets bind to a clot, they disgorge serotonin, where it serves as a vasoconstrictor and helps to regulate hemostasis and blood clotting. Serotonin also is a growth factor for some types of cells, which may give it a role in wound healing.
  6. Majority released from gut Responsible for smooth muscle contractions Release stimulated by foodintake Inhibits release of gastric acid Softens stool Cardiovascular system – vasoconstrictor Bronchioconstriction Uterine contractions
  7. Peripheral Peristalsis Vomiting Platelet aggregation and haemostasis Inflammatory mediator Sensitisation of nociceptors
  8. Central Control of appetite Sleep Mood Hallucinations Stereotyped behaviour Pain perception Vomiting
  9. Actions of 5-HT  Potent depolarizer of Nerve endings – exerts direct as well as Arteries areconstricted (direct) or dilated (EDRF) – depends on vascular bed and basal tone Also releases Adrenaline – affects ganglionic transmission – CVS reflexes Overall, large arteries and veins are constricted but in microcirculation arterioles dilate and veins constrict Constriction of veins – escape offluid indirect effects  Tachyphylaxis
  10. Actions of 5-HT - CVS  Heart: Isolated heart stimulation - direct ionotropic andchronotropic effects ◦ Intact animal Heart: Bradycardia due to stimulation coronary chemoreflex (Bezold Jarrisch reflex) – through vagaus Nerve ◦ Overall bradycardia, hypotension and apnoea  Blood Pressure: Triphasic response on BP ◦ Early sharp fall: Coronary chemoreflex ◦ Brief rise in BP: vasoconstriction and increased cardiac output ◦ Prolonged fallin BP: arteriolar dilatation and extravasation of fluid  (Not involved in Physiological Regulation of BP) – Preeclmpsia  Ketanserin – 5-HT antagonist (5-HT2)
  11. Actions of 5-HT – contd. Platelet: 5-HT2A action – changes in shape and size of platelets– but weak aggregator CNS: Poor entry to BBB – however it’s atransmitter – INHIBITORY ◦ Direct Injection: Hunger, sleepiness, behavioural changes
  12. 5-HT Physiological Roles – contd.  Haemostasis: Platelet aggregation and clot formation enhancer  Raynaud`s phenomenon: Vasospastic  Variant angina: Coronary vasospasm or Variant angina  Hypertension: Not clearly known – reduced uptake and clearance of 5-HT - Ketanserin  Intestinal Motility: Regulates local reflex andperistalsis in gut  Carcinoid syndrome: Massive release – hypermotility and bronchoconstriction  5-HTs – N O THERAPEUTIC USE
  13. Pathphysiological Roles – 5-HT  Neurotransmitter: Raphe nuclei, substancia nigra and other sites….. Send serotonergic to limbic system, cortex, neostriatum and also to Spinal chord – regulates sleep, temperature regulation, thought process, cognitive, behaviour and mood, appetite, vomiting and pain perception  Precursor of Melatonin: Pineal gland  Neuroendocrine Function: Hypothalamic hormones toAnterior Pituitary – serotonergic(!)  Nausea and Vomiting: Cytotoxic drugs and radiotherapy –receptor of gut 5HT3  Migraine: Vasoconstrictor phase of migraine – Methysergide andSumatriptan
  14. N N COOH C NH2 COOH C NH2 OH N C NH2 OH H Tryptophan 5-Hydroxytryptophan 5-Hydroxytryptamine N C COOH 5-OH Indole Acetaldehyde 5-Hydroxy Indole Acetic Acid Tryptophan hydroxylase 5-OH Tryptophan decarboxylase (Rate limiting) In diet. Active CNS transport
  15. B MAO A orB (SERT)
  16. Serotonin receptors
  17. 14 distinct serotonin receptor subtypes The 5-HT1 receptors = largest subfamily The most intensively studied of these has been the 5-HT1A receptor. This subtype is found on both postsynaptic membranes of forebrain neurons primarily in the hippocampus, cortex, and septum and on serotonergic neurons. It also functions as a somatodendritic autoreceptor.
  18. 5–HT1 7 trans–membrane domains G protein linked cAMP dependant Anxiolytic and antidepressant Subtypes  5–HT1A, 5–HT1B, 5–HT1D, 5– HT1E, 5–HT1F 5–HT1A Limbic system  Regulation of emotions Neocortex Hypothalamus Substantia gelatinosa  Proprioception
  19. CNSforum.com
  20. •5-HT1 receptors occur primarily in the brain and cerebral blood vessels (5-HT1D only), where they mediate neural inhibition and vasoconstriction. •They function mainly as inhibitory presynaptic receptors, linked to inhibition of adenylatecyclase. •Specific agonists at 5-HT1 receptors include •Sumatriptan (used in migraine therapy) •Buspirone (used in the treatment of anxiety). •Spiperone and methiothepin are specific antagonists of 5- HT1 receptors.
  21. 5–HT2 7trans–membrane domains G protein linked Phospholipase C dependant Subtypes  5– HT2A ,5– HT2B ,5– HT2C
  22. 5– HT2A Periphery  Contraction of vascular /non–vascular smooth muscle  Platelet aggregation  Increased capillary permeability  Cognitive process of working memory, a function believed to be impaired in schizophrenia.  Modulation of the release of other neurotransmitters and hormones ACh, Adrenaline, Dopamine, Excitatory amino acids, Vasopressin
  23. 5- HT2A CNS  Motor behaviour  Sleep regulation  Nociception  Neuroexcitation
  24. •5-HT3 receptors occur mainly in the peripheral nervous system, particularly on nociceptive afferent neurones and on autonomic and enteric neurones. •The effects of these receptors are excitatory, mediated by receptor- coupled ion channels. •5-HT3 antagonists (eg ondansetron, tropisetron) are used predominantlyas anti-emetic drugs.
  25. 5-HT4 receptors are found in the brain, as well as peripheral organs like the heart, bladder and gastrointestinal (GI) tract. stimulating peristalsis. A specific 5-HT4 agonist ismetoclopramide used for treating gastrointestinal disorders. Little is known about the function and pharmacology of 5-HT5, 5-HT6 and 5-HT7 receptors.
  26. Serotonin has both ascending & decending projections. Ascending serononergic projections Serotonergic neurons are clustered in midline raphe nuclei of the midbrain, pons, and medulla Ascending projections from these nuclei course through the medial forebrain bundle before diverging to many target regions.  median raphe nucleus provides the majority of the serotonergic innervation of the limbic system, including the hippocampus and septum,  dorsal raphe nucleus provides the primary innervation of the striatum and thalamus.
  27. Decendng serononergic projection extend down the brainstem, and through the spinal cord. The caudal raphe serotonergic neurons project to the medulla, cerebellum, and spinal cord. Serotonergic efferents to the dorsal horn of the spinal cord have been implicated in the suppression of nociceptive pathways.
  28. Ascending pathway regulates Mood, Anxiety, Sleep Decending pathway regulate the pain sentation.
  29. 1. Mood Disorders 2. Anxiety Disorder 3. Schizophrenia 4. ADHD 5. Sexual Disorders 6. Impulse Control Disorder 7. Personality disorders 8. Carcinoid syndrome
  30. With the huge effect that the selective serotonin reuptake inhibitors (SSRIs) for example, fluoxetine have made on the treatment of depression, serotonin has become the biogenic amine neurotransmitter most commonly associated with depression. The identification of multiple serotonin receptor subtypes has also increased the excitement within the research community about the development of even more specific treatments for depression. Depletion of serotonin may precipitate depression, and some patients with suicidal impulses have low cerebrospinal fluid (CSF) concentrations of serotonin metabolites and low concentrations of serotonin uptake sites onplatelets.
  31. Different types of acute stress result in increased 5- HT turnover in the prefrontal cortex, nucleus accumbens, amygdala, and lateral hypothalamus.  5-HT release may have anxiogenic and anxiolytic effects, depending on the region of the forebrain involved and the receptor subtype activated. Anxiogenic effects are mediated via 5-HT2A receptor, stimulation of 5-HT1A receptors is anxiolytic.  serotonergic antidepressants have therapeuticeffects in some anxiety disorders for example, clomipramine (Anafranil) in OCD.  The effectiveness of buspirone (BuSpar), a serotonin 5-HT1A receptor agonist, in the treatment of anxiety disorders
  32. Current hypotheses posit serotonin excess as a cause of both positive and negative symptoms in schizophrenia. The robust serotonin antagonist activity of clozapine and other second-generation antipsychotics, coupled with the effectiveness of clozapine to decrease positive symptoms in chronic patients has contributed to the validity of this proposition.
  33. There is weak evidence for the significant involvement of serotonin inADHD. The support for the serotonin hypothesis comes from the fact that some drugs (TCA & MAOI) that affect serotonin metabolism are moderately effective in ADHD. However SSRIs have not been shown to be effective. Thus, if serotonin plays a role in ADHD, it is not likely to have a central role but rather an adjunctive role to one or more other neurotransmitter systems.
  34. SSRIs can cause anorgasmia, erectile dysfunction, diminished libido. Stimulation of postsynaptic 5-HT2 and 5- HT3 receptors =decreases dopamine release from the substantia nigra =Sexual Dysfunction.
  35. Low CSF serotonin metabolites often found in certain depressions. Also are found among people who have made suicide attempts who are violent, impulsive, alcoholics and it has been found among their relatives . Impulsive alcoholic violent offenders have decreased 5-HIAA.
  36. Seretonin in ANOREXIANERVOSA Three neurotransmitters involved in regulating eating behavior in the paraventricular nucleus of the hypothalamus.  Serotonin,  Dopamine,  Norepinephrine. Seretonin in BULIMIANERVOSA Because antidepressants often benefit patients with bulimia nervosa and because serotonin has been linked to satiety, serotonin and norepinephrine have been implicated.
  37. Studies of personality traits and the dopaminergic and serotonergic systems indicate an arousal- activating function for these neurotransmitters. Raising serotonin levels with serotonergic agents such as fluoxetine (Prozac) can produce dramatic changes in some character traits of personality. In many persons, serotonin reduces depression, impulsiveness, and rumination, and can produce a sense of general well-being.
  38. One type of tumor, called carcinoid, sometimes secretes large amounts of serotonin into the blood, which causes various forms of the carcinoid syndrome of flushing, diarrhea, and heartproblems. Because of serotonin's growth- promoting effect on cardiac myocytes, persons with serotonin-secreting carcinoid may suffer a right heart (tricuspid) valve disease syndrome, caused by proliferation of myocytes onto the valve.
  39. Drugs Affecting Serotonergic System
  40. 5-HT1A : Buspirone, Ipsapirone, Tandospirone Treat anxiety, depression (partial agonist) 5-HT 1D/1B : Sumatriptan, Naratriptan, Zolmitriptan Treat migraine (partial agonist) 5-HT 2A/2C : Methysergide, Trazodone, Risperidone, Ketanserin, Ritanserin, Mianserin Treat migraine, depression, schizophrenia (antagonist)
  41. 5-HT 3 : Ondansetron, Granisetron, Tropisetron, Memantine, Mirtazapine The enterochromaffin cells are very sensitive to cancer chemotherapy = vomiting Treat chemotherapy-induced emesis (antagonist) 5-HT 4 : Cisapride, Metoclopramide, Mosapride, Dazopride, Tegaserod Treat GI disorders (agonist) Serotinergic Drugs
  42. Serotonin re–uptake inhibitors Citalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Venlafaxine Clomipramine, Imipramine Nefazodone, Trazodone Chlorpheniramine Cocaine, Dextromethorphan, Pentazocine, Pethidine
  43. Irreversible Monoamine oxidase inhibitors (MAOIs) Clorgyline, Isocarboxazid, Nialamide, Pargyline, Phenelzine, Tranylcypromine Selegiline Furazolidone Procarbazine
  44. Reversible inhibitors of MAO (RIMAs) Brofaramine Befloxatone, Toloxatone Moclobemide
  45. Kaplan and sadock ‘s comprehensive text book of psychiatry. Stephen M. Stahl –Essential Psychopharmacology. Medscape.com Emedicine.com
  46. Thank you
Advertisement